← KRRO
KRRO— Korro Bio, Inc.
MaterialsPharmaceutical Preparations
| Metric | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $0-100.0% | $14.1M-62.0% | $37.0M |
| Research and development | $49.4M-18.9% | $60.9M+62.8% | $37.4M |
| General and administrative | $33.6M-9.7% | $37.2M+37.1% | $27.1M |
| Total operating expenses | $83.0M-15.4% | $98.1M+52.0% | $64.5M |
| Loss from operations | -$83.0M+1.2% | -$84.0M-205.0% | -$27.6M |
| Interest income | $1.3M+234.3% | $397K-60.1% | $994K |
| Interest expense | -$961K-25.8% | -$764K | $0 |
| Realized (loss) gain on investments | $3K+113.0% | -$23K-127.4% | $84K |
| Foreign exchange gain (loss) | -$5K-131.3% | $16K+500.0% | -$4K |
| Other income (expense), net | $1.1M+497.0% | -$266K | — |
| Loss before income taxes | -$81.6M+3.6% | -$84.7M-219.8% | -$26.5M |
| Income taxes | $2K+113.3% | -$15K+57.1% | -$35K |
| Net loss | -$81.6M+3.7% | -$84.7M-219.4% | -$26.5M |
| Net loss per share attributable to common stockholders-basic and diluted | -$2K+5.7% | -$2K | — |
| Weighted-average shares of common stock outstanding-basic and diluted | $35.08B+2.1% | $34.35B+6.5% | $32.25B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.